Skip to main content
Premium Trial:

Request an Annual Quote

FDA Slows Down

Pharmalot's Ed Silverman says the Food and Drug Administration's new, slower pace for drug approvals is probably the "new normal" for the regulatory body. A new study from Parexel Consulting in Boston shows that the rate of first-cycle drug approvals FDA makes is slowing, and that there's a "significant and ongoing decline" in priority-designation rates, Silverman says. Parexel Consulting found a 25 percent decline in first-cycle approvals for new drugs and a 17 percent decline in priority designations for NDAs between 2008 and 2009, which the firm attributes to FDA's Safety First Initiative and new risk management strategies, among other things. Overall, Silverman says, the agency's actions on diabetes drug Avandia are indicative of its "new normal."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.